GlobeNewswire by notified

Van Lanschot Kempen: update on share buy-back programme 22 March 2022 – 28 March 2022

Share

Amsterdam/’s-Hertogenbosch, the Netherlands, 29 March 2022


In the period from 22 March 2022 until 28 March 2022 Van Lanschot Kempen has repurchased 28,897 of its own shares (depositary receipts for Class A ordinary shares). The shares were repurchased at an average price of €23.82 per share for a total amount of €688,369.        

These repurchases are part of the share buy-back programme for at most 600,000 of own shares, which was announced on 24 February 2022. The total number of shares repurchased to date is 144,674.

More information, including a detailed overview of the repurchase transactions under this programme, is available on www.vanlanschotkempen.com/sharebuyback.

Media Relations: +31 20 354 45 85; mediarelations@vanlanschotkempen.com
Investor Relations: +31 20 354 45 90; investorrelations@vanlanschotkempen.com

About Van Lanschot Kempen
Van Lanschot Kempen, a wealth manager active in Private Banking, Investment Management and Investment Banking, with the aim of preserving and creating wealth, in a sustainable way, for both its clients and the society of which it is part. As a sustainable wealth manager with a long-term focus, Van Lanschot Kempen proactively seeks to prevent negative impact for all stakeholders and to create positive long-term financial and non-financial value. Listed at Euronext Amsterdam, Van Lanschot Kempen is the Netherlands’ oldest independent financial services company, with a history dating back to 1737. To fully leverage the potential of the Van Lanschot Kempen organisation for its clients, it provides solutions that build on the knowledge and expertise across its entire group and on its open architecture platform. Van Lanschot Kempen is convinced that it is able to meet the needs of its clients in a sustainable way by offering them access to the full range of its products and services across all its businesses.

For more information, please visit vanlanschotkempen.com

Disclaimer
This press release does not constitute an offer or solicitation for the sale, purchase or acquisition in any other way or subscription to any financial instrument and is not a recommendation to perform or refrain from performing any action.

This press release is a translation of the Dutch language original and is provided as a courtesy only. In the event of any disparities, the Dutch language version will prevail. No rights can be derived from any translation thereof.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

FDA beviljar särläkemedelsstatus för tasquinimod vid behandling av myelofibros18.5.2022 15:00:00 CEST | Pressemelding

Lund 18 maj 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) meddelade idag att amerikanska Food and Drug Administration (FDA) har beviljat särläkemedelsstatus för tasquinimod vid behandling av myelofibros. "Särläkemedelsstatus som FDA tilldelat för tasquinimod i myelofibros utgör ett viktigt steg framåt för Active Biotech", säger Helén Tuvesson, VD Active Biotech. "Det öppnar en viktig regulatorisk väg och ger oss potential att snabbt avancera utvecklingen av tasquinimod i denna patientpopulation.” FDAs Orphan Drug Designation program ger särläkemedelsstatus för läkemedelskandidater avsedda för säker och effektiv behandling, diagnos eller förebyggande av ovanliga sjukdomar som drabbar färre än 200.000 människor i USA. Denna särläkemedelsstatus ger 7 års marknadsexklusivitet vid marknadsgodkännande samt vissa andra fördelar. I februari 2022 ingick Active Biotech ett exklusivt licensavtal med Oncode Institute i Nederländerna, som verkar på uppdrag av Erasmus University Medical Center (

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis18.5.2022 15:00:00 CEST | Press release

Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Helén Tuvesson, CEO Active Biotech. “It opens an important regulatory pathway and provides us with the potential to rapidly advance the development of tasquinimod in this patient population.” The FDA Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnoses or prevention of rare diseases or disorders that affects fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives. In February 2022, Active Biotech entered into an exclusive lice

Kommuniké från årsstämma i Arcoma Aktiebolag den 18 maj 202218.5.2022 14:00:00 CEST | Pressemelding

2022-05-18 PRESSRELEASE Kommuniké från årsstämma i Arcoma Aktiebolag den 18 maj 2022 Idag, den 18 maj 2022, hölls årsstämma i Arcoma Aktiebolag. Årsstämman genomfördes enbart genom förhandsröstning (poströstning) med stöd av tillfälliga lagregler. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet. Beslut om fastställande av räkenskaper samt resultatdisposition Årsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade även att disponera över bolagets resultat i enlighet med styrelsens förslag i årsredovisningens förvaltningsberättelse, innebärande att ingen vinstutdelning lämnas för 2021 samt att disponibla medel balanseras i ny räkning. Ansvarsfrihet åt styrelseledamöterna och verkställande direktören Årsstämman beslutade att bevilja styrelseledamöterna och verkställande direktören ansvarsfrihet för räkenskapsåret 2021. Val och arvodering av styrelse och

Björn Wahlroos will not be available for re-election to Sampo plc’s Board of Directors at the 2023 AGM18.5.2022 13:11:14 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 18 May 2022 Björn Wahlroos will not be available for re-election to Sampo plc’s Board of Directors at the 2023 AGM Björn Wahlroos, Chair of Sampo plc’s Board of Directors, has announced today that he will not be available for re-election to the Board of Directors at the Annual General Meeting to be held in spring 2023. Sampo’s Nomination and Remuneration Committee will communicate on succession in due course. SAMPO PLC For further information, please contact: Sami Taipalus Head of Investor Relations tel. +358 10 516 0030 Distribution: Nasdaq Helsinki London Stock Exchange The principal media Financial Supervisory Authority www.sampo.com

Decisions of Sampo plc’s Annual General Meeting18.5.2022 13:05:00 CEST | Press release

SAMPO PLC DECISIONS OF GENERAL MEETING 18 May 2022 at 2:05 pm Decisions of Sampo plc’s Annual General Meeting The Annual General Meeting of Sampo plc, held today on 18 May 2022, decided to distribute a dividend of EUR 4.10 per share for 2021. The record date for dividend payment is 20 May 2022 and the dividend will be paid on 31 May 2022. The Annual General Meeting adopted the financial accounts for 2021 and discharged the Board of Directors and the CEO from liability for the financial year. The Annual General Meeting increased the number of the members of the Board of Directors to nine members. Christian Clausen, Fiona Clutterbuck, Georg Ehrnrooth, Jannica Fagerholm, Johanna Lamminen, Risto Murto, Markus Rauramo and Björn Wahlroos were re-elected to the Board. Steve Langan was elected as a new member to the Board. The Members of the Board were elected for a term continuing until the close of the next Annual General Meeting. At its organisational meeting, the Board elected Björn Wahlro